Wyszuk. zaawans.

Online first
Wytyczne / stanowisko ekspertów
Opublikowany online: 2025-01-27
Dodaj do koszyka: 95,00 PLN
Wyświetlenia strony 272
Wyświetlenia/pobrania artykułu 39
Pobierz cytowanie

Eksport do Mediów Społecznościowych

Eksport do Mediów Społecznościowych

Terapia chorych z przerzutowym HER2-dodatnim rakiem piersi

Joanna Kufel-Grabowska1, Barbara Radecka23, Katarzyna Pogoda4, Piotr Wysocki5, Anna Niwińska4, Tomasz Kubiatowski6, Maciej Krzakowski7

Streszczenie

Leczenie chorych z zaawansowanym HER2-dodatnim rakiem piersi stanowi poważne wyzwanie. Nowoczesne metody terapeutyczne przyczyniają się do poprawy wyników leczenia poprzez wydłużenie czasu do progresji choroby, zwiększenie czasu całkowitego przeżycia i poprawę jakości życia. 

Niniejsze stanowisko podsumowuje praktyczne opcje terapeutyczne dla chorych z zaawansowanym HER2- dodatnim rakiem piersi, biorąc pod uwagę określone scenariusze: szybko i wolno postępującą chorobę, raka z przerzutami do ośrodkowego układu nerwowego i opon mózgowych, a także leczenie chorych w zaawansowanym wieku. 

Słowa kluczowe: rak piersiprzerzutowy HER2-dodatni rak piersiprzerzuty do mózguterapia chorych na HER2-dodatniego raka piersi

Artykuł dostępny w formacie PDF

Dodaj do koszyka: 95,00 PLN

Posiadasz dostęp do tego artykułu?

Referencje

  1. Vaz-Luis I, Ottesen RA, Hughes ME, et al. Impact of hormone receptor status on patterns of recurrence and clinical outcomes among patients with human epidermal growth factor-2-positive breast cancer in the National Comprehensive Cancer Network: a prospective cohort study. Breast Cancer Res. 2012; 14(5): R129.
    CrossRefPubMed
  2. Konecny G, Pauletti G, Pegram M, et al. Quantitative association between HER-2/neu and steroid hormone receptors in hormone receptor-positive primary breast cancer. J Natl Cancer Inst. 2003; 95(2): 142–153.
    CrossRefPubMed
  3. Wang B, Wang X, Zou Y. Association between hormone receptors and HER-2/neu is age-related. Int J Clin Exp Pathol. 2015; 8(7): 8472–8479.
    PubMed
  4. Pegram M, Jackisch C, Johnston SRD. Estrogen/HER2 receptor crosstalk in breast cancer: combination therapies to improve outcomes for patients with hormone receptor-positive/HER2-positive breast cancer. NPJ Breast Cancer. 2023; 9(1): 45.
    CrossRefPubMed
  5. Schrijver WA, Suijkerbuijk KPM, van Gils CH, et al. Receptor Conversion in Distant Breast Cancer Metastases: A Systematic Review and Meta-analysis. J Natl Cancer Inst. 2018; 110(6): 568–580.
    CrossRefPubMed
  6. Swain SM, Miles D, Kim SB, et al. CLEOPATRA study group. Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA): end-of-study results from a double-blind, randomised, placebo-controlled, phase 3 study. Lancet Oncol. 2020; 21(4): 519–530.
    CrossRefPubMed
  7. Wang R, Smyth LM, Iyengar N, et al. Phase II Study of Weekly Paclitaxel with Trastuzumab and Pertuzumab in Patients with Human Epidermal Growth Receptor 2 Overexpressing Metastatic Breast Cancer: 5-Year Follow-up. Oncologist. 2019; 24(8): e646–e652.
    CrossRefPubMed
  8. Hurvitz SA, Hegg R, Chung WP, et al. Trastuzumab deruxtecan versus trastuzumab emtansine in patients with HER2-positive metastatic breast cancer: updated results from DESTINY-Breast03, a randomised, open-label, phase 3 trial. Lancet. 2023; 401(10371): 105–117; Erratum in: Lancet. 2023; 401(10376): 556.
    CrossRefPubMed
  9. Verma S, Miles D, Gianni L, et al. EMILIA Study Group. Trastuzumab emtansine for HER2-positive advanced breast cancer. N Engl J Med. 2012; 367(19): 1783–1791.
    CrossRefPubMed
  10. Modi S, Saura C, Yamashita T, et al. DESTINY-Breast01 Investigators. Trastuzumab Deruxtecan in Previously Treated HER2-Positive Breast Cancer. N Engl J Med. 2020; 382(7): 610–621.
    CrossRefPubMed
  11. Curigliano G, Mueller V, Borges V, et al. Tucatinib versus placebo added to trastuzumab and capecitabine for patients with pretreated HER2+ metastatic breast cancer with and without brain metastases (HER2CLIMB): final overall survival analysis. Ann Oncol. 2022; 33(3): 321–329; Erratum in: Ann Oncol. 2023; 34(7): 630.
    CrossRefPubMed
  12. Wildiers H, Tryfonidis K, Dal Lago L, et al. Pertuzumab and trastuzumab with or without metronomic chemotherapy for older patients with HER2-positive metastatic breast cancer (EORTC 75111-10114): an open-label, randomised, phase 2 trial from the Elderly Task Force/Breast Cancer Group. Lancet Oncol. 2018; 19(3): 323–336.
    CrossRefPubMed
  13. Orlando L, Lorusso V, Giotta F, et al. Metronomic oral chemotherapy with cyclophosphamide plus capecitabine combined with trastuzumab (HEX) as first line therapy of HER-2 positive advanced breast cancer: A phase II trial of the Gruppo Oncologico Italia Meridionale (GOIM). Breast. 2020; 53: 18–22.
    CrossRefPubMed
  14. Blackwell KL, Burstein HJ, Storniolo AM, et al. Overall survival benefit with lapatinib in combination with trastuzumab for patients with human epidermal growth factor receptor 2-positive metastatic breast cancer: final results from the EGF104900 Study. J Clin Oncol. 2012; 30(21): 2585–2592.
    CrossRefPubMed
  15. Hua X, Bi XW, Zhao JL, et al. Trastuzumab Plus Endocrine Therapy or Chemotherapy as First-line Treatment for Patients with Hormone Receptor-Positive and HER2-Positive Metastatic Breast Cancer (SYSUCC-002). Clin Cancer Res. 2022; 28(4): 637–645.
    CrossRefPubMed
  16. Darlix A, Louvel G, Fraisse J, et al. Impact of breast cancer molecular subtypes on the incidence, kinetics and prognosis of central nervous system metastases in a large multicentre real-life cohort. Br J Cancer. 2019; 121(12): 991–1000.
    CrossRefPubMed
  17. DeBusk K, Ike C, Lindegger N, et al. Real-world outcomes among patients with HER2+ metastatic breast cancer with brain metastases. J Manag Care Spec Pharm. 2022; 28(6): 657–666.
    CrossRefPubMed
  18. Schiff D, Messersmith H, Brastianos PK, et al. Radiation Therapy for Brain Metastases: ASCO Guideline Endorsement of ASTRO Guideline. J Clin Oncol. 2022; 40(20): 2271–2276.
    CrossRefPubMed
  19. Vogelbaum MA, Brown PD, Messersmith H, et al. Treatment for Brain Metastases: ASCO-SNO-ASTRO Guideline. J Clin Oncol. 2022; 40(5): 492–516.
    CrossRefPubMed
  20. Gondi V, Bauman G, Bradfield L, et al. Radiation Therapy for Brain Metastases: An ASTRO Clinical Practice Guideline. Pract Radiat Oncol. 2022; 12(4): 265–282.
    CrossRefPubMed
  21. Shen CJ, Lim M, Kleinberg LR. Controversies in the Therapy of Brain Metastases: Shifting Paradigms in an Era of Effective Systemic Therapy and Longer-Term Survivorship. Curr Treat Options Oncol. 2016; 17(9): 46.
    CrossRefPubMed
  22. Yamamoto M, Serizawa T, Higuchi Y, et al. Stereotactic radiosurgery for patients with multiple brain metastases (JLGK0901): a multi-institutional prospective observational study. Lancet Oncol. 2014; 15(4): 387–395.
    CrossRefPubMed
  23. Kim InAh, Winter KA, Sperduto PW, et al. Concurrent Lapatinib With Brain Radiation Therapy in Patients With HER2+ Breast Cancer With Brain Metastases: NRG Oncology-KROG/RTOG 1119 Phase 2 Randomized Trial. Int J Radiat Oncol Biol Phys. 2024; 118(5): 1391–1401.
    CrossRefPubMed
  24. Kim JM, Miller JA, Kotecha R, et al. Stereotactic radiosurgery with concurrent HER2-directed therapy is associated with improved objective response for breast cancer brain metastasis. Neuro Oncol. 2019; 21(5): 659–668.
    CrossRefPubMed
  25. Niwinska A, Pogoda K, Jagiello-Gruszfeld A, et al. Intracranial Response Rate in Patients with Breast Cancer Brain Metastases after Systemic Therapy. Cancers (Basel). 2022; 14(4).
    CrossRefPubMed
  26. André F, Cortés J, Curigliano G, et al. A pooled analysis of trastuzumab deruxtecan in patients with human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer with brain metastases. Ann Oncol. 2024 [Epub ahead of print].
    CrossRefPubMed
  27. Harbeck N, Ciruelos E, Jerusalem G, et al. DESTINY-Breast12 study group. Trastuzumab deruxtecan in HER2-positive advanced breast cancer with or without brain metastases: a phase 3b/4 trial. Nat Med. 2024 [Epub ahead of print].
    CrossRefPubMed
  28. Niwińska A. Brain metastases as site of first and isolated recurrence of breast cancer: the role of systemic therapy after local treatment. Clin Exp Metastasis. 2016; 33(7): 677–685.
    CrossRefPubMed
  29. Le Rhun E, Weller M, Brandsma D, et al. EANO Executive Board and ESMO Guidelines Committee. EANO-ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up of patients with leptomeningeal metastasis from solid tumours. Ann Oncol. 2017; 28(suppl_4): iv84–iv99.
    CrossRefPubMed
  30. Niwińska A, Rudnicka H, Murawska M. Breast cancer leptomeningeal metastasis: propensity of breast cancer subtypes for leptomeninges and the analysis of factors influencing survival. Med Oncol. 2013; 30(1): 408.
    CrossRefPubMed
  31. Niwińska A, Pogoda K, Michalski W, et al. Determinants of prolonged survival for breast cancer patient groups with leptomeningeal metastasis (LM). J Neurooncol. 2018; 138(1): 191–198.
    CrossRefPubMed
  32. Niwińska A, Rudnicka H, Murawska M. Breast cancer leptomeningeal metastasis: the results of combined treatment and the comparison of methotrexate and liposomal cytarabine as intra-cerebrospinal fluid chemotherapy. Clin Breast Cancer. 2015; 15(1): 66–72.
    CrossRefPubMed
  33. Kumthekar PU, Avram MJ, Lassman AB, et al. A phase I/II study of intrathecal trastuzumab in human epidermal growth factor receptor 2-positive (HER2-positive) cancer with leptomeningeal metastases: Safety, efficacy, and cerebrospinal fluid pharmacokinetics. Neuro Oncol. 2023; 25(3): 557–565.
    CrossRefPubMed
  34. Palma DA, Olson R, Harrow S, et al. Stereotactic Ablative Radiotherapy for the Comprehensive Treatment of Oligometastatic Cancers: Long-Term Results of the SABR-COMET Phase II Randomized Trial. J Clin Oncol. 2020; 38(25): 2830–2838.
    CrossRefPubMed
  35. Harrow S, Palma DA, Olson R, et al. Stereotactic Radiation for the Comprehensive Treatment of Oligometastases (SABR-COMET): Extended Long-Term Outcomes. Int J Radiat Oncol Biol Phys. 2022; 114(4): 611–616.
    CrossRefPubMed
  36. Carola E, Pulido M, Falandry C, et al. First-line systemic treatment with palbociclib in women aged ≥70 years presenting with hormone receptor-positive advanced breast cancer: Results from the PALOMAGE program. J Clin Oncol. 2023; 41(16_suppl): 1018–1018.
    CrossRef
  37. Brain E, Caillet P, de Glas N, et al. HER2-targeted treatment for older patients with breast cancer: An expert position paper from the International Society of Geriatric Oncology. J Geriatr Oncol. 2019; 10(6): 1003–1013.
    CrossRefPubMed
  38. Slamon DJ, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med. 2001; 344(11): 783–792.
    CrossRefPubMed
  39. Marty M, Cognetti F, Maraninchi D, et al. Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group. J Clin Oncol. 2005; 23(19): 4265–4274.
    CrossRefPubMed
  40. Hamberg P, Bos MM, Braun HJJ, et al. Dutch Breast Cancer Trialists' Group (BOOG). Randomized phase II study comparing efficacy and safety of combination-therapy trastuzumab and docetaxel vs. sequential therapy of trastuzumab followed by docetaxel alone at progression as first-line chemotherapy in patients with HER2+ metastatic breast cancer: HERTAX trial. Clin Breast Cancer. 2011; 11(2): 103–113.
    CrossRefPubMed
  41. Andersson M, Lidbrink E, Bjerre K, et al. Phase III randomized study comparing docetaxel plus trastuzumab with vinorelbine plus trastuzumab as first-line therapy of metastatic or locally advanced human epidermal growth factor receptor 2-positive breast cancer: the HERNATA study. J Clin Oncol. 2011; 29(3): 264–271.
    CrossRefPubMed
  42. von Minckwitz G, Schwedler K, Schmidt M, et al. GBG 26/BIG 03-05 study group and participating investigators. Trastuzumab beyond progression: overall survival analysis of the GBG 26/BIG 3-05 phase III study in HER2-positive breast cancer. Eur J Cancer. 2011; 47(15): 2273–2281.
    CrossRefPubMed
  43. Kaufman B, Mackey JR, Clemens MR, et al. Trastuzumab plus anastrozole versus anastrozole alone for the treatment of postmenopausal women with human epidermal growth factor receptor 2-positive, hormone receptor-positive metastatic breast cancer: results from the randomized phase III TAnDEM study. J Clin Oncol. 2009; 27(33): 5529–5537.
    CrossRefPubMed
  44. Vogel CL, Cobleigh MA, Tripathy D, et al. Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol. 2002; 20(3): 719–726.
    CrossRefPubMed
  45. Crown JP, Burris HA, Boyle F, et al. Pooled analysis of diarrhea events in patients with cancer treated with lapatinib. Breast Cancer Res Treat. 2008; 112(2): 317–325.
    CrossRefPubMed
  46. Schwartzberg LS, Franco SX, Florance A, et al. Lapatinib plus letrozole as first-line therapy for HER-2+ hormone receptor-positive metastatic breast cancer. Oncologist. 2010; 15(2): 122–129.
    CrossRefPubMed
  47. Miles D, Baselga J, Amadori D, et al. Treatment of older patients with HER2-positive metastatic breast cancer with pertuzumab, trastuzumab, and docetaxel: subgroup analyses from a randomized, double-blind, placebo-controlled phase III trial (CLEOPATRA). Breast Cancer Res Treat. 2013; 142(1): 89–99.
    CrossRefPubMed
  48. Biganzoli L, Aapro M, Loibl S, et al. Taxanes in the treatment of breast cancer: Have we better defined their role in older patients? A position paper from a SIOG Task Force. Cancer Treat Rev. 2016; 43: 19–26.
    CrossRefPubMed
  49. Wildiers H, Meyskens T, Marréaud S, et al. Long term outcome data from the EORTC 75111-10114 ETF/BCG randomized phase II study: Pertuzumab and trastuzumab with or without metronomic chemotherapy for older patients with HER2-positive metastatic breast cancer, followed by T-DM1 after progression. Breast. 2022; 64: 100–111.
    CrossRefPubMed
  50. Dang C, Iyengar N, Datko F, et al. Phase II study of paclitaxel given once per week along with trastuzumab and pertuzumab in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer. J Clin Oncol. 2015; 33(5): 442–447.
    CrossRefPubMed
  51. Andersson M, López-Vega J, Petit T, et al. The co-administration of pertuzumab (P) and trastuzumab (T) as a single infusion, followed by vinorelbine (V), in first-line (1L) treatment of HER2-positive locally advanced or metastatic breast cancer (MBC) patients (pts): VELVET study interim analysis. J Clin Oncol. 2015; 33(15_suppl): 586–586.
    CrossRef
  52. Krop IE, Kim SB, Martin AG, et al. Trastuzumab emtansine versus treatment of physician's choice in patients with previously treated HER2-positive metastatic breast cancer (TH3RESA): final overall survival results from a randomised open-label phase 3 trial. Lancet Oncol. 2017; 18(6): 743–754.
    CrossRefPubMed
  53. Barrios CH, Anton A, Delalogue S, et al. Safety of trastuzumab emtansine (T-DM1) in a subgroup analysis of the Kamilla study. J Clin Oncol. 2015; 33(suppl): abstr 603.
  54. Diéras V, Harbeck N, Budd GT, et al. Trastuzumab emtansine in human epidermal growth factor receptor 2-positive metastatic breast cancer: an integrated safety analysis. J Clin Oncol. 2014; 32(25): 2750–2757.
    CrossRefPubMed
  55. Buono G, Deleuze A, Klocker EV, et al. 237P Real-world safety and efficacy of trastuzumab-deruxtecan (T-DXd) in HER2-positive advanced breast cancer (ABC) elderly patients (pts): The TREX-Old retrospective registry. ESMO Open. 2023; 8(1): 101425.
    CrossRef
  56. Meattini I, Becherini C, Caini S, et al. Consensus Panellist Group. International multidisciplinary consensus on the integration of radiotherapy with new systemic treatments for breast cancer: European Society for Radiotherapy and Oncology (ESTRO)-endorsed recommendations. Lancet Oncol. 2024; 25(2): e73–e83.
    CrossRefPubMed
  57. Ippolito E, Silipigni S, Matteucci P, et al. Stereotactic Radiation and Dual Human Epidermal Growth Factor Receptor 2 Blockade with Trastuzumab and Pertuzumab in the Treatment of Breast Cancer Brain Metastases: A Single Institution Series. Cancers (Basel). 2022; 14(2).
    CrossRefPubMed
  58. Garcia-Alvarez A, Papakonstantinou A, Oliveira M. Brain Metastases in HER2-Positive Breast Cancer: Current and Novel Treatment Strategies. Cancers (Basel). 2021; 13(12).
    CrossRefPubMed
  59. Khan M, Zhao Z, Arooj S, et al. Lapatinib Plus Local Radiation Therapy for Brain Metastases From HER-2 Positive Breast Cancer Patients and Role of Trastuzumab: A Systematic Review and Meta-Analysis. Front Oncol. 2020; 10: 576926.
    CrossRefPubMed
  60. Murthy RK, Loi S, Okines A, et al. Tucatinib, trastuzumab, and capecitabine for HER2-positive metastatic breast cancer. N Engl J Med. 2020; 382(7): 597–609.
    CrossRefPubMed
  61. Id Said B, Chen H, Jerzak KJ, et al. Trastuzumab emtansine increases the risk of stereotactic radiosurgery-induced radionecrosis in HER2 + breast cancer. J Neurooncol. 2022; 159(1): 177–183.
    CrossRefPubMed
  62. Stumpf PK, Cittelly DM, Robin TP, et al. Combination of Trastuzumab Emtansine and Stereotactic Radiosurgery Results in High Rates of Clinically Significant Radionecrosis and Dysregulation of Aquaporin-4. Clin Cancer Res. 2019; 25(13): 3946–3953.
    CrossRefPubMed
  63. Cortés J, Kim SB, Chung WP, et al. DESTINY-Breast03 Trial Investigators. Trastuzumab Deruxtecan versus Trastuzumab Emtansine for Breast Cancer. N Engl J Med. 2022; 386(12): 1143–1154.
    CrossRefPubMed

Informacje o plikach cookie

Niezbędne pliki cookie

Zawsze aktywne

Te pliki cookie są niezbędne do prawidłowego wyświetlania i działania strony internetowej. Zablokowanie ich może spowodować nieprawidłowe działanie strony.

Analityczne pliki cookie

W ramach naszej strony internetowej korzystamy z narzędzi analitycznych, takich jak Google Analytics, które umożliwiają nam weryfikację ruchu na stronie internetowej. Narzędzia te mogą wymagać użycia plików cookie.

Społecznościowe pliki cookie

Są to pliki cookie powiązane z portalami społecznościowymi, z których korzystamy. Zaakceptowanie ich pozwoli na powiązanie Twojej wizyty na stronie z naszymi profilami w mediach społecznościowych.

Marketingowe pliki cookie

Są to pliki cookie odpowiedzialne za prowadzenie działań reklamowych i marketingowych - zgoda na ich wykorzystanie pozwoli nam kierować do Ciebie reklamy, bazujące na podstawie Twoich wcześniejszych aktywności w ramach naszej stronie internetowej.

Copyright © 2023-2025 Via Medica Regulamin Polityka cookies Polityka prywatności Nota prawna